Glioblastoma (GBM) is one of the most lethal human cancers. Genomic analyses are
defining the molecular architecture of GBM, uncovering relevant subsets of patients whose
disease may require different treatments. Many pharmacological targets have been
revealed, promising to transform patient care through targeted therapies. However, for most
patients, clinical responses to targeted inhibitors are either not apparent or not durable. In
this review, we address the challenge of developing more effective, molecularly guided …